Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | MSC co-infusion with either HLA-mismatched PBSC or cord blood |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mesenchymal stem cell infusion | Procedure | Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Day-100 incidence of non-relapse mortality | 100 days |
| Measure | Description | Time Frame |
|---|---|---|
| 1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution | 365 days |
Not provided
V.1. Patients
V.1.1. Diseases
Hematological malignancies confirmed histologically and not rapidly progressing:
V.1.2. Clinical situations
Theoretical indication for a standard allo-transplant, but not feasible because:
Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.
V.1.3. Other inclusion criteria
V.1.4. Exclusion criteria
V.2. PBSC donors
V.2.1. Inclusion criteria
V.2.2. Exclusion criteria
V.2.3. HLA matching
Related or unrelated donors who have 1-2 HLA mismatches, as either :
V.3. Cord blood unit
Banked cord blood units will be used if they fulfill the following criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederic Baron, MD, PhD | CHU-ULg | Principal Investigator |
| Yves Beguin, MD, PhD | CHU-ULg | Principal Investigator |
| Chantal Lechanteur, PhD | CHU-ULg | Study Chair |
| Etienne Baudoux, MD | CHU-ULg | Study Chair |
| Evelyne Willems, MD | CHU-ULg | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Sart Tilman | Liège | Liege | 4000 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20109568 | Derived | Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| D006086 | Graft vs Host Disease |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D007154 |
| Immune System Diseases |